At Natural Products Expo West, we asked the head of the Natural Products Association (NPA)—Daniel Fabricant, Ph.D.—about kratom, a popular and controversial botanical targeted in recent warning letters by his former employer, FDA. Hear what Fabricant had to say about regulatory issues surrounding kratom in the United States, including claims about its ability to help people addicted to opioids.
This is the second in a three-part video series based on a wide-ranging interview with Fabricant at Expo West, which was held in March in Anaheim, California.
About the Author(s)
You May Also Like
Advancing gender equity in the nutraceutical industrySep 25, 2023
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023
Radicle Insights—Covid Eris and dietary supplements: separating fact from fictionSep 21, 2023